Endothelin-receptor antagonists for aneurysmal subarachnoid hemorrhage: an updated meta-analysis of randomized controlled trials

[1]  S. Mayer,et al.  Randomized Trial of Clazosentan in Patients With Aneurysmal Subarachnoid Hemorrhage Undergoing Endovascular Coiling , 2012, Stroke.

[2]  S. Mayer,et al.  Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2) , 2011, The Lancet Neurology.

[3]  R. Macdonald,et al.  Lower incidence of cerebral infarction correlates with improved functional outcome after aneurysmal subarachnoid hemorrhage , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  R. Macdonald,et al.  Cerebral Infarction After Subarachnoid Hemorrhage Contributes to Poor Outcome by Vasospasm-Dependent and -Independent Effects , 2011, Stroke.

[5]  W. Poon,et al.  Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage: an updated systemic review and meta-analysis , 2011, Critical care.

[6]  R. Macdonald,et al.  Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  Joseph P Broderick,et al.  Definition of Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage as an Outcome Event in Clinical Trials and Observational Studies: Proposal of a Multidisciplinary Research Group , 2010, Stroke.

[8]  Shihong Zhang,et al.  Tirilazad for aneurysmal subarachnoid haemorrhage. , 2010, The Cochrane database of systematic reviews.

[9]  Jeffrey J. Fletcher,et al.  Do Endothelin-Receptor Antagonists Prevent Delayed Neurological Deficits and Poor Outcomes After Aneurysmal Subarachnoid Hemorrhage?: A Meta-Analysis , 2009, Stroke.

[10]  Ale Algra,et al.  Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis , 2009, The Lancet Neurology.

[11]  S. Mayer,et al.  Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1): Randomized, Double-Blind, Placebo-Controlled Phase 2 Dose-Finding Trial , 2008, Stroke.

[12]  A. Dumont,et al.  New insights into the causes and therapy of cerebral vasospasm following subarachnoid hemorrhage. , 2008, Drug discovery today.

[13]  V. Feigin,et al.  Calcium Antagonists for Aneurysmal Subarachnoid Hemorrhage , 2008 .

[14]  A. Algra,et al.  Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[15]  R. Macdonald,et al.  PREDICTORS OF CEREBRAL INFARCTION IN PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE , 2007, Neurosurgery.

[16]  Jürgen Meixensberger,et al.  Continuous Monitoring of Cerebrovascular Autoregulation After Subarachnoid Hemorrhage by Brain Tissue Oxygen Pressure Reactivity and Its Relation to Delayed Cerebral Infarction , 2007, Stroke.

[17]  S. Mayer,et al.  IMPACT OF RED BLOOD CELL TRANSFUSION ON OUTCOME AFTER SUBARACHNOID HEMORRHAGE. , 2006 .

[18]  S. Mayer,et al.  Impact of medical complications on outcome after subarachnoid hemorrhage* , 2006, Critical care medicine.

[19]  B. Meyer,et al.  Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. , 2005, Journal of neurosurgery.

[20]  A. Suhardja.  Mechanisms of Disease: roles of nitric oxide and endothelin-1 in delayed cerebral vasospasm produced by aneurysmal subarachnoid hemorrhage , 2004, Nature Clinical Practice Cardiovascular Medicine.

[21]  V. Feigin,et al.  Circulatory volume expansion therapy for aneurysmal subarachnoid haemorrhage. , 2004, The Cochrane database of systematic reviews.

[22]  D. Connolly,et al.  Regional anaesthesia , 2003, Anaesthesia.

[23]  S. Peery,et al.  Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage , 2002, Neurology.

[24]  D. Stewart,et al.  Temporal Relationship Between Endothelin-1 Concentrations and Cerebral Vasospasm in Patients With Aneurysmal Subarachnoid Hemorrhage , 2001, Stroke.

[25]  G. Murray,et al.  Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group. , 2000, Journal of neurosurgery.

[26]  J. Pickard,et al.  An efficacy and safety study of the ETA/B receptor antagonist TAK-044 in subarachnoid hemorrhage , 2000 .

[27]  C. Anderson,et al.  Health outcomes 1 year after subarachnoid hemorrhage , 2000, Neurology.

[28]  T. Nose,et al.  Endothelin-1 concentration increases in the cerebrospinal fluid in cerebral vasospasm caused by subarachnoid hemorrhage. , 2000, Surgical neurology.

[29]  J. De Keyser,et al.  Use of the Barthel index and modified Rankin scale in acute stroke trials. , 1999, Stroke.

[30]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[31]  E. Macdonald.  Aneurysmal Subarachnoid Hemorrhage , 1989, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[32]  B. Jennett,et al.  ASSESSMENT OF OUTCOME AFTER SEVERE BRAIN DAMAGE A Practical Scale , 1975, The Lancet.

[33]  H. Steiger,et al.  Early CT perfusion measurement after aneurysmal subarachnoid hemorrhage: a screening method to predict outcome? , 2012, Acta neurochirurgica. Supplement.

[34]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[35]  N. Knuckey,et al.  Health outcomes 1 year after subarachnoid hemorrhage , 2000 .

[36]  B Jennett,et al.  Assessment of outcome after severe brain damage. , 1975, Lancet.